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Abstract
Purpose: To review cross-linking the cornea using riboflavin and ultraviolet A
light, which has been widely adopted, refined and applied in a range of corneal
surgeries and pathologies where the strength of the cornea might be compro-
mised.
Recent findings: A large number of clinical trials have been carried out, most of
which have demonstrated that standard cross-linking is a successful method to
halt the progression of keratoconus or even aid regression.
Summary: This review describes our current understanding of the technique,
focussing on how cross-linking works, how the treatment is being optimised, the
clinical results that have been reported to date and the potential use of the therapy
in the treatment of other corneal disorders.
Introduction
The potential of ultraviolet-A light (UVA) to cross-link tis-
sues in the presence of the non-toxic photosensitising agent
riboflavin had been known for some time, but it was not
until 1998 that a group from Dresden suggested it as a
potential therapeutic treatment to strengthen the corneal
stroma. The concept was based on the observation that nat-
urally occurring protein cross-linking, which accelerates
with age, strengthens and stiffens the cornea. This suggested
that artificial cross-linking may have a similar effect, partic-
ularly in conditions such as keratoconus, where the constit-
uent collagen is prone to enzymatic degradation and
fibrillar slippage. This review discusses the development of
corneal cross-linking (commonly referred to as CXL) with
riboflavin and UVA, the basic scientific principles behind
the technique and its success as a treatment option for ker-
atoconus and other corneal disorders. It also explores issues
of safety, side-effects and long-term prognosis to provide
Ophthalmologists and Optometrists with the necessary
information to advise patients on possible treatment
options and eligibility for cross-linking.
Mechanism of cross-linking
There is considerable experimental evidence supporting the
creation of cross-link formation following CXL: increased
stiffness,1 increased resistance to proteolytic enzymes such
as collagenase,2 reduced corneal permeability3 and forma-
tion of large collagen molecular aggregates when examined
by SDS electrophoresis.4 The chemical process is believed
to start with the excitation of riboflavin into its excited sin-
glet and triplet states. Two mechanisms are then possible,
one of which (Type I) is favoured at low oxygen concentra-
tions producing radicals or radical ions, and the second
(Type II) in which excited riboflavin reacts with oxygen to
produce singlet molecular oxygen (1O2).
5 Under aerobic
conditions, which occur during the initial 15 seconds expo-
sure to UVA, sensitised photo-oxidation of stromal pro-
teins occurs mainly by its reaction with reactive oxygen
species such as (1O2) – a Type II reaction.
6 After this brief
phase, oxygen is depleted and the reaction between ribofla-
vin and proteins is predominantly Type I. The reactive spe-
cies can then, in principle, induce covalent cross-linking of
many different molecules including, in the corneal stroma,
collagens, proteoglycans (extracellular matrix molecules
consisting of a protein core to which are attached sulphated
glycosaminoglycans), DNA and RNA. Lesions in nucleic
acids are cytotoxic and lead to apoptosis of keratocytes
and, unless precautions are taken, also to endothelial cells.
The riboflavin is crucial to the process – applied to the
anterior stroma it induces the cross-links, while at the same
time absorbing the ultraviolet radiation and thus prevent-
ing damage to the posterior layers of the cornea.5,7
At present, it is still not known exactly what the nature
of the cross-links is, and precisely where they occur within
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the extracellular matrix. Carbonyl and free amine groups
are commonly involved in cross-linking processes. A care-
ful study by McCall et al.8 showed that, following CXL, car-
bonyl-based cross-links dominate in the cornea, with
relatively little cross-linking of free amine groups. It
appears that the carbonyl-dependent cross-linking involves
the formation of advanced glycation endproducts, similar
to those that result from non-enzymatic glycosylation.9
Figure 1 shows one such cross-link that may occur. This
type of cross-link could involve amino acids such as histi-
dine, hydroxyproline, hydroxylysine, tyrosine, and threo-
nine,8 but the exact amino acids involved in cross-linking,
and their molecular locations, remain to be determined.
The constituents of the cornea involved in cross-linking
are also unknown. Theoretically cross-linking could occur
not just between collagen molecules but also between colla-
gens and proteoglycan core proteins. Zhang et al.10 have
studied interactions between the various constituents of the
extracellular matrix, both in isolation and within the tissue.
Their results are summarised in Table 1. It was evident that
collagen could not only cross-link with itself but also with
two proteoglycan core proteins – mimecan and decorin.
The core proteins could cross-link to themselves but the
attached sulphated glycosaminoglycans (keratan sulphate
and chondroitin sulphate) were not involved in cross-link-
ing. Interestingly, after cross-linking, decorin appeared to
form distinct dimers rather than large aggregates like the
other proteoglycan core proteins.
Swelling studies have also shed light on the location of
cross-links. In an in vitro study, Wollensak et al.11 demon-
strated that cross-linked pig corneas placed in a humidity
chamber swell less than untreated corneas. However, the det-
urgescent agent dextran is normally included to limit swell-
ing caused by the riboflavin, and it was not clear whether the
altered swelling properties were caused by the presence of
dextran within the cross-linked tissue or whether it was due
to the cross-links themselves. In a more recent study in
which corneal buttons were allowed to swell freely in saline
solution (and consequently leach proteoglycans and ribofla-
vin solution from the tissue), we found no difference
(Figure 2) in the swelling rate of CXL treated, riboflavin-only
treated, or untreated corneas,12 suggesting the absence of sig-
nificant collagen-proteoglycan cross-linking.
Hayes et al.12 also showed that CXL does not increase
the bulk separation between adjacent collagen molecules
within fibrils, as would be expected if cross-links such as
the one shown in Figure 1 were to occur throughout the
fibril. This, together with their swelling results, led the
authors to conclude that cross-linking predominates within
and between molecules on the fibril surfaces, and within
proteoglycan core proteins in the interfibrillar space.12 If
the latter is the case, it may be that the term “collagen
cross-linking”, so often used to describe CXL, is in fact an
incomplete description of the mechanism.
Effect of treatment on the cornea: biomechanics
CXL significantly increases corneal rigidity immediately
after treatment, with an 80% increase of Young’s modulus
in pigs and a 450% increase in the thinner human cornea at
6% strain.13 Longer term in vitro studies in rabbits have
confirmed that the stiffening effect persists at eight months
after treatment.1 Later reports have demonstrated that the
stiffening is depth-dependent, being confined mostly to the
anterior 200 lm or so of the cornea.14–16 In fact, 70% of
the incident UVA is absorbed within the anterior 200 lm
and 90% within the anterior 400 lm.14
The ocular response analyser provides two in vivo mea-
sures of corneal biomechanical properties, corneal hysteresis
Figure 1. Example of a likely Advanced Glycation Endproduct (AGE)
cross-link formed following CXL.8 The size of the bond limits the inter-
protein distances that can be cross-linked.
Table 1. Cross-linking that occurs (Y) and does not occur (N) between corneal stromal macromolecules (based on the results of Zhang et al.10)
Molecule Collagen Keratocan Lumican Mimecan Decorin Keratan Sulphate Chondroitin Sulphate
Collagen Y N N Y Y N N
Keratocan N Y – – – – –
Lumican N – Y – – – –
Mimecan Y – – Y – –
Decorin Y – – – Y – dimer
Keratan Sulphate N – – – – N N
Chondroitin Sulphate N – – – N N
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(a measure of viscous damping) and corneal resistance factor
(related to the viscoelastic resistance of the cornea to defor-
mation). These parameters have lower values in keratoconus
patients and appear to be unaltered after CXL.17 However,
corneal hysteresis is not correlated with Young′s modulus
and the ocular response analyser only measures the viscoelas-
tic properties in a sagittal direction using an air-puff system
whereas stress/strain measurements are made in the tangen-
tial direction. In fact, this has been confirmed by Wollensak
et al.18 who showed that collagen cross-linking does not
change the interlamellar cohesion force thus allowing an
interlamellar sliding movement19 that is not affected by
cross-linking. This study also shed light on the mechanism
of cross-linking, showing that it probably does not halt kera-
toconus progression by preventing lamellar slippage.
Effect of treatment on the cornea: structure
The effects of CXL on the various structures within the cor-
neal stroma have been studied by a number of imaging tech-
niques, both in vivo and ex vivo. Immunofluorescence
confocal microscopy revealed a highly organised anterior
fluorescence zone with a compaction of the collagen bun-
dles following CXL.20 Transmission electron microscope
studies showed that there was a 12% increase in the constit-
uent collagen fibril diameters within this anterior region,
providing direct evidence that the collagen fibrils themselves
were involved in the cross-linking process.21 This was sup-
ported by enzyme digestion experiments that showed that
CXL confers the collagen with markedly increased resistance
to pepsin, trypsin and collagenase.2 However, x-ray scatter-
ing studies failed to support the finding of increased fibril
diameters in cross-linked corneas.12 It is hypothesised that
cross-linked corneas may appear to have relatively larger fibril
diameters than untreated tissue when viewed by electron
microscopy as the newly formed cross-links may provide
greater resistance to the tissue shrinkage that is known to
occur during tissue processing for electron microscopy.
Cross-linking has also been imaged using non-linear
microscopy.22,23 In an in vivo rabbit study, two-photon
microscopy was employed to visualise and quantify the col-
lagen cross-linking following CXL by means of collagen’s
intrinsic autofluorescence; a strong autofluorescence signal
was generated from cross-linked collagen that allowed the
cross-linked region to be clearly demarcated from the un-
cross-linked region.23 It has since been shown in human
corneas that the boundary between cross-linked and un-
cross-linked tissue occurs at a stromal depth of about
300 lm from the anterior surface in epithelium-debrided
cross-linked corneas.24 In the case of epithelium-intact
treated corneas the cross-linked region is limited to the
anterior 90–110 lm of the tissue.25
UVA treatment is known to be associated with cytotoxic-
ity. The original studies on the effects that irradiation has
on stromal keratocytes used cell cultures treated with
0.025% riboflavin solution and a range of UVA irradiances.
An abrupt cytotoxic level occurred at 0.5mW cm2, which
was 10-fold lower than when riboflavin was omitted.26
Using the standard irradiance methods, this cytotoxic level
was expected to be reached down to a stromal depth of
300 lm. This was confirmed by examination of enucleated
rabbit corneas, removed 24 h after standard CXL, which
revealed complete depletion of keratocytes down to a depth
of 300 lm.27 This leads to several questions – when CXL is
carried out in humans is the cornea repopulated by acti-
vated keratocytes and if so, how long does the re-popula-
tion take, and is fibrotic connective tissue laid down by the
keratocytes during the process? To address some of these
questions, a second phase prospective non-randomised
study was carried out in 10 keratoconus patients treated
with CXL. In vivo confocal microscopy showed a loss of
keratocytes in the anterior and mid-stroma immediately
after treatment. After 3 months, keratocytes had repopu-
lated the exposed area and the initial oedema disappeared.
At 6 months, keratocyte repopulation was complete,
accompanied by an increased density of collagen fibres.28
However, it is known that the collagen, proteoglycans and
keratocytes in keratoconus are abnormal29–31 and there still
remains no ultrastructural study of precisely what these
(presumably keratoconic) migrating cells are doing in
terms of collagen and proteoglycan deposition when they
repopulate the stroma, and therefore to what extent a “nor-
mal” stromal ultrastructure is being attained, if at all.
Safety
A major concern when irradiating the cornea with UVA is
the safety aspects associated with endothelial cell damage and
corneal sensitivity if nerves are injured. This aspect has been
Figure 2. Untreated (left), standard CXL treated (middle) and 2.5%
glutaraldehyde treated (right) corneal buttons shown following immer-
sion in saline solution for 24 h. The hydration of the untreated and CXL
treated corneas increased from H = 5.5 to H = 14 whilst the glutaralde-
hyde -treated cornea increased from H = 5 to H = 6. The cross-links
formed by glutaraldehyde fixation restrict tissue swelling in vitro
whereas those formed by CXL do not; this is likely due to difference in
the nature and location of the cross-links.
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comprehensively covered in a separate review32 so will only be
briefly discussed here. In vitro cell culture studies have been
carried out by the Dresden group on rabbits33 and pigs.34
Apoptosis was detected histologically using either TUNEL33
or trypan blue/Yopro staining.34 In both cases an abrupt
endothelial cytoxicity occurred for 370 nm wavelength at an
irradiance level close to 0.36 mWcm2. To protect the endo-
thelial cells therefore requires precise knowledge of how much
radiation penetrates the stroma, and that in turn requires
careful measurement of the absorption coefficient and the
effects of riboflavin. This parameter has been measured in
human donor corneas with and without riboflavin. The ribo-
flavin led to a 50% increase in absorbance after 30 minutes of
riboflavin treatment,35 with an absorbance coefficient of
56.36  4.80 cm1 although other workers have found a sig-
nificantly lower value36 which may be a cause for concern.
This level of absorbance has been calculated to yield a UVA
irradiance at a depth of 400 lm of 0.18 mWcm2, which is
less than half the toxic level32 and for this reason, the maxi-
mum thickness of the cornea that can be treated by the stan-
dard method was set at 400 lm. The very small amount of
riboflavin and UVA that penetrate the cornea is thought not
to affect the aqueous, which in any case contains high levels of
ascorbate, a free radical scavenger.32
Another cause for concern is the possibility that the cor-
neal limbus, in which the epithelial stem cells are located,
may be damaged during CXL. A prospective non-rando-
mised clinical trial found no damage to the limbus34 but an
in vitro study showed cytotoxicity and reduced cell expan-
sion of human limbal epithelial cells37 following riboflavin/
UVA exposure. Therefore, as an added protection it is
advised that polymethacrylate rings or other forms of mask-
ing should be used to ensure absolute limbal protection, par-
ticularly in low-compliance patients who cannot maintain
fixation adequately during the 30 min CXL procedure.34
Corneal nerves are damaged during CXL mostly as a
consequence of the epithelial removal process. Immediately
after CXL the subepithelial plexus and anterior/mid-stro-
mal nerve fibres disappear. In humans and rabbits, regener-
ation of nerve fibres is complete after about 6 months34,38
and plexus structure after 1 year.34 Corneal sensitivity
recovers quickly and is completely normal six months39 to
one year after treatment.38,40
Patient selection for CXL
Although CXL is not recommended in patients with a cor-
neal thickness of less than <400 lm (due to the risk of endo-
thelial damage), in some cases, a hypotonic riboflavin
solution may be used to increase the pre-operative stromal
thickness of thin keratoconus corneas to 400 lm and allow
CXL to be performed.41 Another postulated contraindication
for CXL is a history of incisional refractive surgery (such as
radial keratotomy or astigmatic keratotomy), as it has been
suggested that post-CXL alterations within the corneal
stroma might cause the keratotomy incisions to rupture.42
However, evidence for this complication is uncertain and
indeed recent reports have indicated that CXL may have a
role in actually halting ectasia induced by radial keratoto-
my.43 It has been suggested that CXL is unlikely to benefit
patients with central corneal opacities and associated poor
best-corrected visual acuity and so other treatment options
(e.g. graft surgery) should be considered for such cases.42
Severe dry eye is a further contraindication as it may hinder
re-epithelialisation and thereby increase the risk of post-sur-
gery infection32,42; such conditions should be managed with
punctual plugging and lubricants before considering
CXL.32,42 This is also true of patients with conjunctival ver-
nal disease, where cases of sterile keratitis have been
reported.44 In such eyes, pre-operative management with
topical steroids and even systemic immune-suppressives
should be instigated to ensure any conjunctival atopic dis-
ease is in full remission before considering CXL. Similarly,
corneal melting in eyes after CXL with herpes simplex kerati-
tis have been reported and therefore caution must be advised
in such eyes, where systemic prophylaxis with anti-herpetic
medication is probably a sensible precaution.45 It has also
been noted that CXL treatment of patients with a preopera-
tive keratometry reading of >58 D presents a greater risk of
continued keratoconus progression46 and permanent post-
operative stromal haze.47 Additionally, patients over the age
of 35 years old with a preoperative corrected distance visual
acuity of better than 20/25 have a higher risk of complica-
tions (loss of two or more Snellen lines) than younger
patients.46 On the basis of these findings it has been pre-
dicted that by restricting treatment eligibility criteria to
include only those under the age of 35 years with a maxi-
mum keratometry reading of less than 58 D the frequency of
complications and failures may be reduced to less than
1%.46 As keratoconus progression is more frequent and fas-
ter in patients under the age of 18 years than in older
patients and has a higher probability of culminating in the
need for corneal transplantation,48,49 Caporossi et al.50 have
recommend that standard CXL be the first choice therapy
for progressive keratoconus in patients under 26 years of
age, provided they meet with all other safety requirements
for the treatment. At present it is felt that the treatment of
pregnant and nursing mothers and patients with systemic
collagen diseases should be delayed until sufficient investiga-
tions into the safety of the treatment in these populations
has been carried out.42
Standard procedure
The standard procedure suggested for clinical use involves
anaesthetising the eye (for example with proxymetacainhy-
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drochloride 0.5% drops) under sterile conditions and then
removing the central 7–9 mm of the epithelium. A ribofla-
vin solution (0.01% riboflavin-5-phosphate and 20% dex-
tran T-500) is then applied to the corneal surface every 5
min for 30 min before irradiation and at 5 min intervals
during the course of a 30 min exposure to 370 nm UVA
radiation, calibrated prior to surgery with a UV light meter
at 3 mWcm2 (Figure 3). A wavelength of 370 nm was
chosen as this corresponds to the absorption peak for ribo-
flavin and an irradiance of 3 mWcm2 was selected to
avoid potential UV overdose.5,51 The purpose of removing
the epithelium is to allow penetration of riboflavin (MW
456) which would otherwise be prohibited by the epithelial
cells’ tight junctions.52 After treatment, antibiotic eye drops
are applied and a therapeutic soft contact lens with good
oxygen transmissibility may be placed upon the eye to
decrease pain without decreasing the quality of the regrow-
ing epithelium.42 Application of topical antibiotics is
required for 1 week after the operation and mild steroids
may also be prescribed. Patients are usually pain-free
within 5–7 days when the contact lens is removed.42
Patients are typically reviewed at day 1 and 5 and again at
months 1, 6 and 12 post-surgery.53
Clinical trials
A large number of clinical trials have been carried out,
nearly all of which have demonstrated that standard CXL is
a successful method to halt the progression of keratoconus
or even aid regression. The results of several of these inves-
tigations are summarised in Table 2. Widely accepted
parameters for evaluating the clinical outcome of refractive
corrections and CXL include uncorrected visual acuity and
corrected visual acuity. Uncorrected visual acuity is usually
measured from a distance chart without the use of contact
lenses or spectacles, representing the habitual vision status
of the eye. Corrected visual acuity is also measured on a
distance chart, referring to the best available vision, and
depending upon the context, may represent the use of con-
tact lenses, spectacles, or both. In the last case this is
described as best corrected visual acuity. However, it
should be noted that visual acuity of any kind is a highly
subjective measure in a keratoconic subject.54 Classically,
keratoconus induces significantly large magnitudes of irreg-
ular astigmatism, higher-order aberrations and some for-
ward light-scattering (even for keratoconic eyes without
apical stromal scarring, such as those undergoing CXL)55
which are each partly responsible for the poor and more
often than not variable best corrected visual acuity achieved
for patients with this disease. Consequently, keratoconic
patients suffer from substantial glare in addition to refrac-
tive error. Keratoconic patients also demonstrate increased
irregular cylinder56 and increased higher order aberra-
tions57 compared to normal eyes. Variations in visual acu-
ity results measured in keratoconic eyes is likely to be due
to the large variability in the measurement of high cylinder
powers58 and to the variability in higher order aberrations
(for example, due to changes in fixational saccadic eye
movements59 and variations in the pre-corneal tear film
between blinks or changes with increasing accommodation,
as demonstrated by Radhakrishnan et al.57).
Although a lesser measure of visual function, topo-
graphical information may be viewed as a more objective
way of assessing the outcome of treatment. Keratometry
measures the power of the principle meridians of the
cornea in dioptres (D). This provides two figures in an
astigmatic cornea, Kmax which represents the steeper
meridian and Kmin the flattest. Kmax is used as a measure
to assess the severity of keratoconus and a decrease or
absence of change in Kmax demonstrates cone flattening
or stability, respectively. This parameter may be measured
manually using a keratometer, automatically using an
autokeratometer that may also measure refraction, or
‘simulated K’s’ may be derived from topographical (cor-
neal topography) information of the whole cornea. As the
purpose of CXL is to halt the ectasia associated with kera-
toconus, Kmax is the parameter consistently measured to
assess the effectiveness of the treatment. Stability or reduc-
tion in Kmax has therefore been the measure used to
assess the percentage of patients for whom CXL had been
an effective treatment (Table 2).
The outcome parameters chosen for inclusion in Table 2
are therefore uncorrected and corrected visual acuity,
improvement in keratometry (Kmax) (although it should
be noted that different techniques have been used to
Figure 3. Standard CXL involves exposing the epithelium-free central
cornea (pre-soaked with riboflavin) with UVA light for 30 minutes, with
the addition of more riboflavin every 5 minutes. Image courtesy of Dr.
Peter Hersh, Hersh Vision Group.
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measure this parameter), and the percentage of patients
seeing stability or regression. For consistency, Table 2
shows the maximum duration of each trial and the number
of eyes examined at the start and end of the trial – it should
be noted that in most trials, fewer eyes were examined
towards the latter stages due to drop out of subjects. Due to
variation in the literature, changes in uncorrected visual
acuity and best corrected visual acuity are sometimes
reported in lines and sometimes in LogMAR.
The first published clinical trial was carried out by Wol-
lensak et al.51 and showed that CXL was effective in halting
the progression of keratoconus. Further trials have con-
firmed that Kmax may be reduced by 2 D or more, with
modest increases in visual acuity (Table 2). Raiskup-Wolf
et al.,60 used a much larger cohort and confirmed the gen-
eral conclusions of the earlier work regarding the efficacy of
the technique in halting progression, and subsequent trials
continue to support these findings. All trials have indicated
a time-dependence of the effects of CXL, both in terms of
transient haze and oedema in the early stages, as well as in
refractive outcome, which seems to improve over the first
year or more following treatment. Long-term comparative
analysis showed that functional results after CXL among
paediatric and young patients (up to 26 years) were better
than in patients over 27 years.50
The majority of the studies listed in Table 2 showed no
significant changes in intraocular pressure, where this was
measured, or in endothelial cell density. There is some dis-
agreement as to the effects of the treatment on corneal
thickness. Some authors reported no long-term
change,46,61,62 whereas Raiskup-Wolf et al.,60 showed a
small reduction of 21  31 lm. On the other hand,
Derakhshan et al.63 reported a small but significant average
increase of 9.1 lm. A careful evaluation of corneal thick-
ness by Greenstein et al.64 showed that there is an initial
thinning of the cornea which then recovers towards base-
line.
The reduction in Kmax noted in most studies, indicated
that in many patients CXL leads to regression of the symp-
toms of keratoconus by flattening the cornea. The causes of
Table 2. Results from published clinical trials using the standard CXL procedure
Name
Maximum
follow-up
time
No. of treated
eyes at start/end
of study
Mean age
(yr)
% Halted or
(improved)
assessed by
Kmax change
Mean
post-operative
reduction in
Kmax value at
end of study
Mean increase
in uncorrected
visual acuity at
end of study
Mean increase
in corrected
visual acuity
at end of study
Wollensak
et al.51
4 years 23/2 31.7 95.5 (70) 2.01 D ? 1.26 lines
Caporossi
et al.61
3 months 10/10 31.4 ? 1.9 D 3.6 lines 1.66 lines
Raiskup-Wolf
et al.60
6 years 241/5 30.04 81 (57) 2.44 D ? 0.18 LogMAR
Jankov et al.139 6 months 25/25 28 100 (52) 2.14 D -0.11 LogMAR 0
Wittig-Silva
et al.140
12 months 33/9 26.9 (>50) 1.45 D ? 0.12 LogMAR
Vinciguerra
et al.141
2 years 28/28 Age
range
24–52
? 1.35 D -0.24 LogMAR -0.15 LogMAR
Agrawal142 1 year 37/37 16.9 92 (54) 2.47 D ? >1line
Coskunseven
et al.62
1 year 19/19 22 ? 1.57 D -0.06 LogMAR 0.10 LogMAR
Koller et al.46 1 year 117/105 ? 92.4 (37.1) ? ? ?
El-Raggal143 6 months 15/15 26.4 ? 1.63 D 0.04 LogMAR 0.02 LogMAR
Koller et al.144 1 year 192/155 29.3 98 (37.7) 0.89 D ? 0.55 LogMAR
Derakhshan
et al.63
6 months 31/31 22.3 90.3 (77) 0.65 D 2.0 lines 1.7 lines
Asri145 1 year 142/64 24.12 90.2 (21.3) 0.49 D 0 0.01 LogMAR
Hersh et al.146 1 year 49/49 ? 89.8 (51.0) 2.0 D 0.05 LogMAR 0.14 LogMAR
O’Brart et al.147 18 months 24/22 29.6 100 (23) ? 0.07 Snellen
decimal
equivalent
0.1 Snellen
decimal
equivalent
Guber et al.66 1 year 33/33 26.36 ? 0.16 D ? 0.042 LogMAR
Viswanathan
and Males148
4 years 51/? 24.25 ? 0.96 D ? 0.05 LogMAR
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this flattening are as yet unknown. Vinciguerra et al.65 con-
cluded that the refractive outcomes were achieved by a
simultaneous flattening of the cone apex and a steepening
of the part of the cornea symmetrically opposite the cone.
It has been suggested that flattening results from the con-
tractive properties of the keratocytes as they migrate to
repopulate the wound.66 There may also be some rear-
rangement of the collagen and the surrounding matrix
brought about by cross-linking.67 Tu et al.68 explained the
effect by considering the stiffening/shortening effect of col-
lagen fibrils on a non-central cone, claiming that CXL
would tend to pull the cone towards the corneal centre,
thus leading to a flattening effect. This raises the interesting
question of whether or not the effects of CXL would
depend on the position of the cone. Finite element model-
ling does indeed suggest that this is the case and that the
topographic effects of CXL may be greatest if treatment is
centred on the cone.69
Recently, initial results have been presented indicating
that CXL is also effective in treating recurrent keratoc-
onus.70 Three cases were examined and in all cases, Kmax
and best corrected visual acuity were stabilised, suggesting
that CXL can arrest the progression of recurrent keratoc-
onus after penetrating keratoplasty.
Side effects
In addition to the pain and potential visual loss caused by
epithelial removal in the first few post-operative days,71 sev-
eral other potential complications of CXL have been
reported, some temporary and some not. It is estimated that
re-epithelialisation requires at least four days for completion
and up to three months for qualitative improvement of the
epithelial cell mosaic compared with the pre-operative
state.34 Stromal haze typically develops during the first few
weeks or months after surgery which can result in transient
deterioration of an already compromised visual perfor-
mance.34 Haze has been reported to be greatest at one
month, to plateau at 3 months, then to significantly decrease
between 3 and 12 months.72 This haze has a distinctive spa-
tial profile; at one month is was noted to be more pro-
nounced in the superficial stroma, gradually diminishing to
zero at 240 lm, and more pronounced in the centre than 1–
3 mm from the centre.73 This is in accordance with confocal
microscope observations of keratocyte apoptosis and repop-
ulation. At 6 months a second region of light scatter
appeared between 240 lm and 340 lm corresponding to
the “demarcation line” which Seiler and Hafezi24 have sug-
gested results from some difference in refractive index or
reflectivity between the cross-linked and the deeper un-
cross-linked regions. Permanent corneal haze (leading to a
loss of two or more lines of corrected visual acuity) has been
shown to occur in approximately 8.6% of all treated eyes.47
Because CXL involves de-epithelialisation followed usually
by the application of a bandage contact lens, there is always
the risk of infection. There have been several case studies
reporting the development of keratitis.74–77 Another case
report described sterile keratitis as a result of pre-existing ver-
nal keratoconjunctivitis,44 emphasising the importance of
careful selection of patients with other pre-existing conditions,
whether these are being treated or not. Corneal melting has
also been reported, often associated with infections.78,79 How-
ever, there are other reports of melting and perforation that
do not appear to have a clear explanation80,81 and this sug-
gests that there may still be unresolved issues regarding the
safety of the technique or the way it is performed.
Reports of other side effects of the treatment are sporadic.
There have been accounts of irreversible endothelial damage,
even when CXL was apparently carried out appropriately,
which have resulted in the need for penetrating keratoplas-
ty.82 Corneal permeability was measured in vivo by monitor-
ing the time course of pilocarpine on pupil diameter, and
ex vivo by measuring fluorescein diffusion. In both cases,
permeability was significantly reduced following CXL.3 This
reduced permeability may have consequences for the diffu-
sion of nutrients through the cornea as well as for the intra-
ocular penetration of topically applied medications, so long-
term studies are required. Similarly, there is some debate as
to the effects of CXL on intraocular pressure. While most
reports indicate no significant changes,60,61,83 Kymionis
et al.84, in a study of 55 eyes from 55 patients, showed that
intraocular pressure remained elevated by 14% one year after
cross-linking. These elevated levels were not correlated with
patient age, pachymetry or preoperative keratometry. Cos-
kunseven et al.62 also found that intraocular pressure
increased significantly by up to 6 mmHg. At present it is not
clear if elevated intraocular pressure in some patients persists
in the longer term and what, if any, would be the long term
effects on vision of this elevated pressure.
Modifications to the standard procedure
1. To reduce patient discomfort
One clinical drawback of the standard CXL procedure is
the postoperative discomfort associated with the removal
of the corneal epithelium, which can be mild to severe and
last for several days. In addition to this, epithelial debride-
ment can lead to complications such as wound infection
and other problems related to the activation of the wound
healing responses in the stroma. Consequently, some
authors have suggested modifications in which the proce-
dure is carried out without epithelial removal.85,86 How-
ever, in vitro studies in pig corneas have shown that
riboflavin penetration through the intact epithelium is
minimal,87 and is patchy if the epithelium is partially dis-
rupted.88 Follow-on in vivo human studies have confirmed
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the need for complete removal of the epithelium52,89 when
standard CXL is performed, although not all clinicians
agree and the debate continues.89,90
Recently, several methods of trans-epithelial cross-link-
ing have been proposed in which the anti-swelling agent
dextran is typically omitted on the basis that its high molec-
ular weight may inhibit the penetration of riboflavin solu-
tion across the epithelium. In these procedures, chemical
agents, such as benzalkonium chloride (BAC),91 EDTA25 or
gentamycin54 are added to the riboflavin solution (individ-
ually or in combination) to loosen the tight junctions of
the epithelial cells and thereby facilitate passage of ribofla-
vin into the stroma without the need for epithelial removal.
Although transepithelial cross-linking by these methods
undoubtedly offers patients a faster and less invasive treat-
ment than can be provided by the standard technique and
facilitates the treatment of paediatric and uncooperative
patients as well as those with thinner corneas (nearing
380 lm), its effectiveness remains uncertain. Experimental
comparative studies in rabbit corneas have shown that
cross-linking of corneas with an intact epithelium using
BAC 0.0005% results in an increase in biomechanical rigid-
ity (Young’s modulus) of about one-fifth of that induced
by standard CXL with epithelial debridement (21.30% vs
102.45%)92; this is presumably due to limited riboflavin
absorption, since increasing the concentration of BAC to
0.02% produces an increase in the absorption co-efficient
and an increase in Young’s modulus.93 It is not yet known
whether the full stiffening effect of the standard CXL treat-
ment is actually needed to stop keratoconus progression or
whether the effects produced by trans-epithelial cross-link-
ing may be sufficient. The latter is supported by two pro-
spective cohort studies25,54 and one non-randomised
retrospective study,94 with follow-up times of up to 1254,94
and 1825 months which have independently found signifi-
cant improvements in visual and topographic outcome
measures after trans-epithelial CXL. The long term efficacy
and side effects of each procedure need to be ascertained by
longer follow-up, randomized, controlled studies.
Several other new approaches to cross-linking are also
being investigated. Daxer et al.95 have proposed a technique
to treat keratoconus whereby a flexible full-ring implant is
placed into a “closed” corneal pocket into which the ribofla-
vin is instilled, thus avoiding the need to remove the epithe-
lium91 or use other drugs. Iontophoretic delivery of
riboflavin (using a mild electrical current) also holds prom-
ise as a useful modification to the standard protocol as it
could greatly reduce the time required for administering
riboflavin, and possibly also eliminate the need for epithelial
removal96 (Figure 4). According to Dr George O Waring IV,
riboflavin is especially suitable for delivery by this method
since it has a low molecular weight, is negatively charged at
physiological pH levels and is highly water soluble.96
2. To reduce treatment time
With the aim of reducing treatment time and increasing
the throughput of patients, investigators are now considering
the use of higher illumination intensities in the CXL
Figure 4. Schematic showing iontophoretic delivery of riboflavin into the corneal stroma. A negatively charged delivery electrode is placed on the
cornea and a counter electrode (small plaster patch) is placed on the patient’s forehead. A low intensity electrical current flows between the two elec-
trodes to drive riboflavin solution across the intact epithelium and into the corneal stroma.
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procedure. In the standard CXL procedure 3 mWcm2 is
applied to a 9 mm treatment zone for 30 min, resulting in a
total energy dose of 3.4 J or a radiant exposure of 5.4 Jcm2.
However, this same level of radiant exposure can be achieved
by applying a higher intensity for a shorter time, and studies
conducted on pig corneas have shown that increasing the illu-
minance intensity to 10 mWcm2 and reducing the exposure
time to 9 min produces a similar increase in corneal stiffness
to that gained using the standard procedure.97 The safety of
using higher intensities in vivo has not yet been examined.
3. To facilitate the treatment of very thin keratoconic cor-
neas
In order to overcome the contra-indication of treating
corneas with a thickness bordering on 400 lm, Kymionis
et al.98 developed the use of pachymetry-guided epithelial
debridement- a treatment modification in which the epi-
thelium is only removed from regions of the cornea with a
thickness in excess of 400 lm. Although the safety and
efficacy of the treatment has yet to be fully validated, a
study of 2 patients revealed that no adverse events had
occurred during the treatment and after 9 months, both
the corneal topography and endothelial cell density
remained unchanged. An alternative solution for the treat-
ment of very thin corneas was proposed by Hafezi et al.41
They suggested replacing the standard iso-osmolar ribofla-
vin solution (containing dextran) with a hypo-osmolar
riboflavin solution (without dextran) to swell the cornea
to an acceptable thickness prior to cross-linking.41 X-ray
scattering studies have shown that this phenomenon of
increasing corneal thickness in cross-linked corneas is
caused not by an increase in the diameter of the collagen
fibrils but by an increase in the spacing between individual
fibrils.99 Using the modified technique, Hafezi et al.41 trea-
ted 20 patients with thin corneas (minimum preoperative
stromal thickness of 323 lm) and reported a cessation of
keratoconus progression in all cases. However, the tech-
nique is not without limitations and CXL failure has been
reported following the treatment of an extremely thin cor-
nea (preoperative minimal thickness after abrasion of
268 lm).100 The outcome of this case led the authors to
suggest that a minimal preoperative stromal thickness of
330 lm is required for successful CXL using the modified
protocol.100
Other uses of CXL
1. Non-keratoconus ectasia
In recent years, several authors have reported the suc-
cessful use of CXL to treat other forms of non-keratoconus
ectasia, such as pellucid marginal degeneration101–104 or
keratectasia following LASIK105–108 and radial keratoto-
my.43 In all cases, an arrest and even a partial reversal in the
ectasia was seen after cross-linking. In fact Hafezi and Is-
eli109 have so far been the only ones to report an exacerba-
tion of keratectasia despite CXL. They described a case in
which a pregnant woman developed bilateral iatrogenic
keratectasia 26 months after LASIK surgery. CXL was per-
formed on both eyes and a regression in ectasia was
observed at 22 months follow-up. However, the patient’s
subsequent pregnancy led to an exacerbation of the keratec-
tasia, possibly as a result of hormonal changes during preg-
nancy altering the biomechanical properties of the cornea.
2. Stabilisation of corneoplastic procedures
Although the corneoplastic effects of intra-corneal ring
segment implantation generally remain stable for many
years,110 CXL is being considered as a useful adjunct to the
procedure to further stabilise the altered corneal shape. The
development of this combination treatment is in its early
stages and the optimal time to perform each stage of the
treatment has yet to be ascertained.111–113 Combining LASIK
with CXL may result in improved corneal integrity and
thereby reduce instances of post-LASIK keratectasia. Indeed,
a recent study investigating this found that patients treated
with combined LASIK and CXL had a similar or slightly bet-
ter clinical outcome than those treated with LASIK alone.114
The use of CXL with topography-guided photorefractive
keratectomy was first described by Kanellopoulos and Bin-
der.115 Since then, Kymionis et al.116 have shown that the
simultaneous treatment of topography-guided photorefrac-
tive keratectomy followed by CXL for keratoconus results
in reduced refractive error and keratometry readings and
improvements in visual acuity that remain stable at a mean
follow-up of nearly 20 months. Similar results have been
obtained by Stojanovic et al.103 However, it is worth noting
that in vitro studies of untreated and CXL treated pig cor-
neas have shown that the efficacy of laser ablation is lower
in CXL treated corneas117 and so it may be necessary to
modify existing ablation algorithms for the treatment of
cross-linked corneas.117
Further investigations into the use of CXL as a means of
stabilising corneal moulding have produced mixed results.
Early studies of accelerated CXL in combination with
microwave keratoplasty (a novel technique used to induce
axial shrinkage of collagen and thereby flatten the keratoc-
onus cornea), found it to be only minimally effective as an
adjunct to the procedure as it failed to maintain the flatten-
ing effect and regression occurred.118 When used in con-
junction with orthokeratology it was found that CXL failed
to stabilise the moulding effect (corneal topography and
wave front error returned to baseline levels within 1 month
of orthokeratology interruption) but nevertheless resulted
in improved visual acuity, which remained above baseline
levels 1 year after the combined treatment was per-
formed.119
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3. Infectious keratitis
The antimicrobial properties of CXL against common
bacterial and fungal pathogens were demonstrated in vitro
by Martins et al. in 2008.120 Due to its ability to inhibit
pathogen growth CXL is seen as a promising treatment
option for the management of cases of infectious keratitis
which are unresponsive to antibiotic therapy, and the clin-
ical studies support this.121,122 In a study involving 40
patients with infectious keratitis, the use of CXL and con-
tinued antibiotic treatment resulted in 85% of the cases
being resolved without the need for emergency penetrating
keratoplasty.122 It was noted however that the success rate
was higher for bacterial infections than fungal infections
and that the treatment should be avoided in eyes with
prior herpes simplex. The encouraging results of another
study involving 16 patients, in which CXL was used as a
primary treatment for bacterial keratitis123 indicate that
larger randomized trials are warranted to compare the
benefits of CXL treatment with customary antibiotic ther-
apy in terms of the healing time and complication fre-
quency.
4. Oedema
On the basis of Wollensak et al.11 demonstrating that
cross-linked pig corneas placed in a humidity chamber
swell less than untreated corneas, CXL was proposed as a
therapeutic option for the treatment of conditions involv-
ing corneal oedema. In a study of 25 eyes of 25 patients in
which CXL was used to treat oedema related to Fuchs
endothelial dystrophy, corneal graft failure, and postopera-
tive bullous keratopathy, the mean corneal thickness was
found to be significantly reduced following treatment.124
However, at 3 months follow-up 56% of the patients had
developed epithelial bullae and only 44% of the 25 patients
remained asymptomatic at 6 months follow-up.124 Two
other studies describing CXL treatment of bullous keratop-
athy reported significant reductions in pain, irritation and
discomfort but no change in corneal thickness and visual
acuity.125, 126 Another showed short term improvements in
pain, corneal thickness and transparency but found no last-
ing effects.127 With the aim of producing more favourable
and longer lasting results, others have tried modified CXL
techniques in which the oedematous cornea is dehydrated
to a normal thickness prior to treatment by means of a
1 day pre-treatment of 40% glucose128 or a 30 minute pre-
treatment of 70% glycerol.129 Using these methods, distinct
reductions in corneal thickness and patient discomfort have
been reported immediately after treatment129 and at
8 months follow-up.128 Although CXL may not prevent the
need for corneal transplantation in conditions involving
corneal oedema it has the potential to improve the patient’s
visual comfort and extend the time interval for an upcom-
ing corneal transplantation.128
Frequently asked questions
Corneal cross-linking with riboflavin and UVA has to date
been carried out on tens of thousands of patients with a
very high success rate. Nevertheless, from the discussion
above it is clear that there are still a number of questions
that need to be answered. We conclude by seeking opinions
from some leading experts in this field about some of the
most common questions.
1. At what point should a patient be referred for cross-
linking?
Mr D. O’Brart, Guy’s and St Thomas’ NHS Foundation
Trust, UK
My indication at present for CXL is to perform it in
any suitable patient (adequate corneal thickness, K max
less than 58D, no central scarring, age typically less
than 40) with reported or documented evidence of pro-
gression, although that is changing to any such suitable
patient with keratoconus or ectasia, as it not only halts
progression but also improves corneal shape.
2. Can the patient return to wearing soft contact lenses
after cross-linking?
Prof. Dr. F. Hafezi, University of Geneva, Switzerland
Contact lens wear can be started again, once the exam at
4 weeks after CXL shows that the corneal epithelium is
well closed and without irregularities. Between month 1
and 6, reduced sensitivity might be an issue, and we
advise to not excessively wear contact lenses during that
period and have the cornea checked regularly. I do not
think that contact lens wear should be an issue after
these 6 months. Please note that at 6 months after CXL,
an assessment of the anterior corneal curvature will be
made. To properly assess the cornea, the patients should
refrain from wearing contact lenses for 2 weeks to avoid
misinterpretation due to corneal warpage.
3. How long is the treatment expected to last? Will
re-treatments be needed?
Prof. Dr. E. Spoerl, Augenklinik Universit€atsklinikum,
Dresden, Germany
The half-life-time of the cornea is about 7 years and
with cross-linking this half-life time will be increased
thus we can expect that the CXL effect should last
more than 10 years. However, under certain situa-
tions such as pregnancy,109,130–134 neurodermatitis,60
stress and hormonal changes135,136 and application of
prostaglandins,137,138 a new progression of keratoc-
onus can occur in spite of CXL. In our series of 730
eyes which we cross-linked since 1998 the rate of
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re-CXL is about 2.5%. For that reason a yearly control
of the cornea by topography (until another measure-
ment device for the corneal biomechanical parameters
is available) is also necessary after CXL to detect slight
changes before worsening of the vision and if neces-
sary a re-CXL should be performed immediately.
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